He has extensive experience in target selection lead generation and lead optimisation against kinase and non kinase targets with a specialisation in covalent drug discovery along with publishing a number of papers on kinases richard is a co inventor of the egfr mutant kinase inhibitor osimertinib. With more than 49 fda approved small molecules the field of kinase inhibition continues to attract significant investment from the drug discovery and development community the 9th rsc sci symposium on kinases will encompass plenary lectures on emergent topics and case studies of ongoing programmes . Now published in the rsc drug discovery series kinase drug discovery edited by richard a ward and frederick w goldberg kinase drug discovery remains an area of significant interest across the pharmaceutical industry and academia. Kinase inhibition remains an area of significant interest across academia and in the pharmaceutical industry there are now many marketed drugs which target kinases and a significant number of compounds are currently in various stages of clinical development although there have been a number of publications on kinase inhibition this is the first to examine the future opportunities and . Kinase drug discovery rsc rsc drug discovery document other than just manuals as we also make available many user guides specifications documents promotional details setup documents and more kinase drug discovery rsc rsc drug discovery are becoming more and more widespread as the most viable form of literary media today
How it works:
1. Register Trial Account.
2. Download The Books as you like ( Personal use )